How Much Does Dayvigo (Lemborexant) Cost in Alaska in 2026?

Alaska Retail Pricing: What You Will Actually Pay

The gap between Eisai's $320/month wholesale acquisition cost and what Alaska residents pay out of pocket is significant. Across retail pharmacies statewide, the average cash price for a 30-day supply of Dayvigo sits at approximately $85/month in 2026.

This discount reflects pharmacy benefit manager (PBM) negotiated rates, manufacturer rebates, and competitive pressure from other insomnia medications. Rural Alaska pharmacies may charge slightly more due to distribution logistics, but the statewide average holds relatively steady. Costco, Fred Meyer, and Walmart pharmacies in Anchorage and Fairbanks typically cluster near the $80 mark. Independent pharmacies in smaller communities like Juneau or Sitka may price closer to $95.

Price variability exists between pharmacy chains. A 2024 analysis of orexin receptor antagonist pricing showed retail markups ranging from 12% to 38% above acquisition cost depending on the pharmacy's PBM contract [1]. Checking GoodRx, RxSaver, or calling pharmacies directly remains the most reliable way to find the lowest local price. Lemborexant received FDA approval in December 2019 based on the SUNRISE-1 trial, which demonstrated statistically significant improvements in sleep onset and maintenance versus placebo in adults with insomnia disorder (N=1,006) [2].

Alaska Medicaid Does Not Cover Dayvigo

Alaska's Medicaid program does not include lemborexant on its preferred drug list. This means beneficiaries cannot obtain Dayvigo through standard Medicaid pharmacy benefits without pursuing an exception.

The Alaska Department of Health classifies dual orexin receptor antagonists as non-preferred agents. Medicaid recipients must first trial and fail generic alternatives, specifically zolpidem or trazodone, before a prior authorization request for Dayvigo would even be considered. Approval rates for these exceptions remain low based on reporting from Alaska's Drug Utilization Review Board.

For Medicaid enrollees who cannot tolerate first-line agents, documentation of adverse reactions or therapeutic failure must come from the prescribing clinician. The appeal process typically takes 14 to 21 days. The American Academy of Sleep Medicine's 2023 clinical practice guideline lists DORAs including lemborexant among recommended pharmacologic options for chronic insomnia, which may support medical necessity arguments in prior authorization appeals [3].

Alaska Medicaid's formulary committee last reviewed DORA-class agents in Q3 2025 and maintained the non-preferred status. No scheduled re-review date has been published.

Insurance Coverage for Dayvigo in Alaska

Commercial insurance plans in Alaska vary widely in their coverage of lemborexant. Premera Blue Cross Blue Shield of Alaska, the state's largest commercial insurer, covers Dayvigo on Tier 3 (non-preferred brand) with prior authorization required.

Moda Health plans available through the Alaska exchange also cover Dayvigo but require step therapy. Patients must document failure on at least one generic sleep agent before approval. Copays for Tier 3 agents on most Alaska commercial plans range from $50 to $75/month.

Federal Employee Health Benefit (FEHB) plans, which cover a substantial portion of Alaska's workforce given the federal presence in the state, generally include Dayvigo with standard prior authorization. The Endocrine Society's guidelines on sleep pharmacotherapy note that DORAs carry lower abuse potential than benzodiazepine receptor agonists, a clinical distinction that supports coverage arguments for patients with substance use history [4].

Tricare, covering military families at Joint Base Elmendorf-Richardson and Eielson Air Force Base, lists Dayvigo as a non-formulary agent requiring Tier 3 prior authorization. The copay structure runs $53/month for a 30-day retail fill.

The Eisai Savings Card: How It Works in Alaska

Eisai offers a manufacturer copay savings card that reduces out-of-pocket costs for commercially insured patients. Eligible Alaska residents can pay as little as $30/month for Dayvigo with the card active.

Eligibility requirements are straightforward. You must have commercial insurance (not Medicare, Medicaid, or other government programs), be 18 or older, and have a valid prescription. The card covers up to $100 in copay assistance per monthly fill, with an annual maximum of $1 to 200 in savings.

Enrollment happens online or through the prescriber's office. The card applies at any participating Alaska pharmacy. One limitation: the savings card does not apply to deductible-phase costs on high-deductible health plans until the patient's pharmacy deductible is met. For patients on HDHP plans common among Alaska's oil and gas workforce, the first few months of the year may still carry full cash-pay pricing.

According to FDA labeling for Dayvigo, the recommended starting dose is 5 mg taken no more than once per night, immediately before bedtime, with at least 7 hours remaining before planned awakening [5]. The savings card applies equally to both the 5 mg and 10 mg tablet strengths.

Compounded Lemborexant in Alaska: Legal and Available

Compounded lemborexant is legally available in Alaska through licensed 503A compounding pharmacies. This route offers an alternative for patients who need dose customization or cannot access the branded product.

Alaska follows federal compounding regulations under the Drug Quality and Security Act (DQSA). A 503A pharmacy operating in Alaska may compound lemborexant with a valid patient-specific prescription from a licensed prescriber. The compound must use bulk drug substance from an FDA-registered supplier, and the pharmacy must comply with Alaska Board of Pharmacy compounding standards.

Cost through 503A compounding pharmacies can be substantially lower than retail branded Dayvigo. Some patients report accessing compounded lemborexant for minimal cost when their compounding pharmacy offers membership or subscription pricing models.

Key distinctions from the branded product: compounded versions may come in capsule form rather than tablets, dose flexibility allows for increments not available commercially (e.g., 2.5 mg or 7.5 mg), and bioequivalence is not FDA-verified the way generic drugs would be [6]. Patients should discuss this trade-off with their prescriber.

503B outsourcing facilities may also ship compounded lemborexant into Alaska without patient-specific prescriptions for office use, though this pathway applies primarily to clinic-dispensed medications rather than retail patient access.

Telehealth Prescribing of Dayvigo in Alaska

Alaska permits telehealth prescribing of lemborexant without geographic restriction. This is particularly relevant given Alaska's size and the concentration of sleep specialists in Anchorage and Fairbanks.

The Alaska State Medical Board allows clinicians to prescribe Schedule IV controlled substances (Dayvigo's DEA classification) via telehealth after establishing a valid provider-patient relationship through audiovisual encounter. No in-person visit is required for initial prescribing. This follows the DEA's updated telehealth prescribing framework that extended pandemic-era flexibilities [7].

For rural Alaska residents, telehealth eliminates the barrier of traveling hundreds of miles to see a sleep medicine specialist. Platforms operating in Alaska can prescribe Dayvigo after conducting a clinical evaluation that documents insomnia symptoms, reviews sleep hygiene measures attempted, and screens for contraindications including narcolepsy, severe hepatic impairment, and concurrent strong CYP3A inhibitor use.

The SUNRISE-1 trial established lemborexant's efficacy at both 5 mg and 10 mg doses versus placebo, with the 10 mg dose showing greater sleep maintenance benefit (wake after sleep onset reduced by 29 minutes versus placebo at Month 1) [2]. Telehealth prescribers in Alaska can initiate therapy at 5 mg and titrate remotely based on patient response.

Comparing Dayvigo to Alternatives Available in Alaska

Lemborexant is not the only DORA available, and Alaska patients should understand comparative pricing and efficacy when making formulary decisions with their providers.

Suvorexant (Belsomra) carries a similar retail price point in Alaska ($90 to $110/month cash pay) and has broader Medicaid coverage in some states, though Alaska Medicaid excludes both DORAs. Generic suvorexant became available in 2023, dropping its cash price significantly below branded Dayvigo.

The SUNRISE-2 trial (N=949) demonstrated lemborexant's long-term safety and sustained efficacy over 12 months, with no evidence of rebound insomnia upon discontinuation [8]. This long-term data distinguishes lemborexant from older hypnotics where rebound effects and dependence are documented concerns.

Zolpidem (generic Ambien) remains the cheapest insomnia medication in Alaska at $8 to $15/month for generic tablets. Trazodone, used off-label, costs $4 to $10/month. These agents serve as step-therapy requirements for insurance authorization of Dayvigo but carry different side-effect profiles. Zolpidem's complex sleep behaviors and next-morning impairment risk contrast with lemborexant's more targeted orexin-pathway mechanism.

Dr. Andrew Krystal, lead investigator of the SUNRISE trials, noted in the JAMA Network Open publication: "The dual orexin receptor antagonist mechanism offers a fundamentally different approach to insomnia treatment by reducing wake drive rather than broadly suppressing CNS activity" [2].

How to Get the Lowest Price on Dayvigo in Alaska

Several strategies can reduce your Dayvigo costs below the $85 average cash-pay price in Alaska.

First, the Eisai savings card brings commercially insured copays to $30/month. Second, 90-day mail-order fills through PBMs like Express Scripts or CVS Caremark often discount per-unit cost by 10% to 15% compared to retail 30-day fills. Third, GoodRx and similar discount platforms occasionally beat standard cash pricing at specific Alaska pharmacies.

For uninsured patients, Eisai's patient assistance program (Eisai Assistance Program) provides Dayvigo at no cost to qualifying households earning below 400% of the federal poverty level. Given Alaska's higher cost-of-living adjustments, the income threshold is more generous than in lower-48 states. Application requires income documentation and a signed prescription from a licensed prescriber.

The National Institutes of Health sleep research portfolio identifies DORAs as a priority therapeutic class, and ongoing post-marketing studies may expand approved indications. Until patent expiry (expected 2032), no generic lemborexant will enter the U.S. market [9].

Patients filling at military pharmacies (Tricare home delivery) or VA pharmacies in Anchorage may access Dayvigo at federal pricing, which typically runs 40% to 60% below retail depending on the formulary tier.

Safety Considerations and Alaska-Specific Factors

Alaska's extreme seasonal light variation creates unique pharmacotherapy considerations for insomnia patients. During summer months with near-continuous daylight, sleep-onset insomnia prevalence increases across the state. Lemborexant's mechanism of blocking wake-promoting orexin signaling may offer particular benefit during these high-light periods compared to agents that rely on enhancing sleep drive alone.

The FDA prescribing information warns against use with alcohol and notes that somnolence is the most common adverse event (reported in 7% of patients on 5 mg and 10% on 10 mg versus 1% placebo) [5]. Alaska's alcohol-use rates, among the highest nationally per CDC behavioral risk data, make this interaction counseling especially relevant for prescribers in the state.

Lemborexant has no renal dose adjustment requirement and requires only avoidance (not dose reduction) in severe hepatic impairment. The moderate hepatic impairment recommendation is to limit dosing to 5 mg nightly [5]. For Alaska's aging population in remote communities with limited hepatology access, this straightforward dosing profile simplifies telehealth management.